1
Ohlmeyer Michael, Bohnstedt Adolph, Kingsbury Celia, Ho Koc Kan, Quintero Jorge, You Ming, Park Haengsoon, Lu Yingchun: Purine and imidazopyridine derivatives for immunosuppression. Pharmacopeia, Ohlmeyer Michael, Bohnstedt Adolph, Kingsbury Celia, Ho Koc Kan, Quintero Jorge, You Ming, Park Haengsoon, Lu Yingchun, HANSEN Philip, October 12, 2006: WO/2006/108103 (69 worldwide citation)

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).


2

3

4
Mcguinness Brian F, Le Thuy Xh, Duo Jingqi, Ho Koc Kan: 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders. Ligand Pharmaceuticals, Mcguinness Brian F, Le Thuy Xh, Duo Jingqi, Ho Koc Kan, FREDERICKS Kellie S, July 16, 2009: WO/2009/089192 (14 worldwide citation)

The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):


5

6
Roughton Andrew, Rong Yajing, Ho Koc Kan, Ohlmeyer Michael, Diller David, Chan Ray Jui Hsiang, Lai Gaifa: Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors. Pharmacopeia, Roughton Andrew, Rong Yajing, Ho Koc Kan, Ohlmeyer Michael, Diller David, Chan Ray Jui Hsiang, Lai Gaifa, FREDERICKS Kellie, May 14, 2009: WO/2009/062059 (10 worldwide citation)

A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKCϑ inhibitors, and their methods of use are disclosed. The genus is represented by the Formula (I).


7
Ohlmeyer Michael, Bohnstedt Adolph, Kingsbury Celia, Ho Koc Kan, Quintero Jorge: 7-substituted purine derivatives for immunosuppression. Pharmacopeia, Ohlmeyer Michael, Bohnstedt Adolph, Kingsbury Celia, Ho Koc Kan, Quintero Jorge, HANSEN Philip, May 22, 2008: WO/2008/060301 (7 worldwide citation)

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula (III).


8
Letourneau Jeffrey John, Ho Koc Kan, Ohlmeyer Michael J, Jokiel Patrick, Riviello Christopher Mark: Azinone and diazinone v3 inhibitors for depression and stress disorders. Pharmacopeia, Letourneau Jeffrey John, Ho Koc Kan, Ohlmeyer Michael J, Jokiel Patrick, Riviello Christopher Mark, HANSEN Philip E, December 14, 2006: WO/2006/133242 (7 worldwide citation)

Substituted pyridines, pyrimidines, pyrazines, pyridinones, pyrimidinones, pyrazinones and phenylacetamides useful in treating depression, stress and other disorders are disclosed. The compounds are of the formulae: (I).


9
Roughten Andrew, Rong Yajing, Ho Koc Kan, Ohlmeyer Michael, Diller David: Purinones and 1h-imidazopyridinones as pkc-theta inhibitors. Pharmacopeia, Roughten Andrew, Rong Yajing, Ho Koc Kan, Ohlmeyer Michael, Diller David, BELL Charles E, November 27, 2008: WO/2008/143674 (6 worldwide citation)

A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKC&THgr; inhibitors, and their methods of use are disclosed. The genus is represented by the formula (I). A representative example is: (II).


10
XU Yong, BRENNING Benjamin Gary, KULTGEN Steven G, LIU Xiaohui, SAUNDERS Michael, HO Koc Kan: [fr] INHIBITEURS DE PROTÉINE KINASE HÉTÉROCYCLIQUES, [en] HETEROCYCLIC PROTEIN KINASE INHIBITORS. XU Yong, BRENNING Benjamin Gary, KULTGEN Steven G, LIU Xiaohui, SAUNDERS Michael, HO Koc Kan, TOLERO PHARMACEUTICALS, HARWOOD Eric A, January 24, 2013: WO/2013/013188 (6 worldwide citation)

[en] The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment ...